F. M. Waldman

TL;DR: It is shown, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations.

TL;DR: An improved CGH technique is described, which enables reliable detection of copy number changes in archival formalin-fixed paraffin-embedded tumor samples and has wide applicability in tumor pathology, allowing large retrospective prognostic studies of genetic aberrations as well as studies on genetic pathogenesis of solid tumors.

TL;DR: This genome-wide overview by comparative genomic hybridization suggests that genetically advanced node-negative breast cancers having a high overall number of genetic aberrations may have a poor prognosis and that increased copy number of two specific regions, 8q and 20q13, may confer a more aggressive phenotype.

TL;DR: A new technique, Comparative Genomic Hybridization (CGH), is developed, which allows rapid detection of DNA amplification anywhere in the tumor genome and maps the amplified sequences on normal chromosomes.

TL;DR: The arrangement of erbB-2 signals in clusters in all amplified cases suggests that erb B-2 amplification occurs intrachromosomally in bladder cancer.